证券代码：688076 证券简称：诺泰生物 公告编号：2025-049 江苏诺泰澳赛诺生物制药股份有限公司 关于自愿披露签订战略合作协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"或"诺泰生 物"）与南京诺唯赞生物科技股份有限公司（以下简称"诺唯赞"）近日于南京市 签署《合成生物学合作项目战略合作协议》（以下简称"战略合作协议"或"协 议"），以合成生物学技术平台为基础，结合有机合成、化学工艺等交叉技术，共 同推进双方在合成生物学领域的技术进步和项目合作。 公司拟与诺唯赞共同设立一家生物制药公司（以下简称"合资公司"或 "项目公司"，具体名称待定，以市场监督管理机关登记的最终名称为准），公司 持股比例为 51%，诺唯赞持股比例为 49%，合资公司设立后将被纳入公司合并报 表范围内，以此为平台开展后续合作及具体业务。合作项目的具体投资规模、建 设方案等事项将由双方另行约定并履行内部审议程序，尚具有不确定性。本投资 事项不构成关联交易，也不构成重大资产 ...

诺唯赞公告，公司与诺泰生物签署《合成生物学合作项目战略合作协议》，并计划共同设立一家生物制 药公司，公司持股比例为49%，诺泰生物持股比例为51%。该合资公司将作为平台，推进双方在合成生 物学领域的技术进步和项目合作。合作项目的具体投资规模、建设方案等事项将由双方另行约定并履行 内部审议程序。合资公司未来业务开展受多方面因素影响，存在不确定性。 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.80元 每股转增0.40股 本次利润分配及转增股本方案经公司2025年5月23日的2024年年度股东大会审议通过。 二、分配、转增股本方案 1.发放年度：2024年年度 本次利润分配及转增股本以方案实施前的公司总股本224,870,915股为基数，每股派发现金红利0.80元 （含税），以资本公积金向全体股东每股转增0.40股，共计派发现金红利179,896,732.00元，转增 89,948,366股，本次分配后总股本为314,819,281股。 三、相关日期 ■ 四、分配、转增股本实施办法 1.实施办法 （1）本次权益分派的现金红利委托中国结算上海分公司通过其资金清算系统向股权登记日上海证券交 易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办理指定交易的投资者 可于红利发放日在其指定的证券营业部领取现金红利，未办理指定交易的股东红利暂由中国结算上海分 公司保管，待办理指定交易后再进行派发。 （2）公司本次以资本公积转增股 ...

Key Points - The company has completed the listing and circulation of all shares from its initial strategic placement [1] - There is no involvement in differentiated dividend distribution or capital increase [1] - The profit distribution and capital increase plan was approved at the annual general meeting on May 23, 2025 [2] - The total share capital before the distribution was 224,870,915 shares, with a cash dividend of 0.80 RMB per share and a capital increase of 0.40 shares per share [2][3] - The total cash dividend distributed amounts to 179,896,732 RMB, and the total shares after the distribution will be 314,819,281 [2][6] - The cash dividend will be distributed through the China Securities Depository and Clearing Corporation Limited Shanghai Branch [2] - For individual shareholders, the tax treatment on dividends varies based on the holding period, with different tax rates applied [4][5] - The company will not withhold corporate income tax for institutional investors, who will be responsible for their own tax payments [6]

证券代码：688076 证券简称：诺泰生物 公告编号：2025-048 江苏诺泰澳赛诺生物制药股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 新增无限售条件流 | 现金红利发放日 | | --- | --- | --- | --- | | | | 通股份上市日 | | | 2025/6/11 | 2025/6/12 | 2025/6/12 | 2025/6/12 | 一、通过分配、转增股本方案的股东大会届次和日期 本次利润分配及转增股本方案经公司2025 年 5 月 23 日的2024年年度股东大 会审议通过。 二、分配、转增股本方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 公司存在首发战略配售股份，首发战略配售股份已全部上市流通 是否涉及差异化分红送转：否 每股分配比例，每股转增比例 每股现金红利0.80元 每股转增0.4 ...

Group 1: Market Performance - The three major indices collectively rose on June 4, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683.SH) increasing by 0.54% [1] - Notable performers within the index included Shouyao Holdings, which rose nearly 9%, and Zhixiang Jintai, which increased over 5% [1] - The Sci-Tech Innovation Medicine Index ETF (588700) experienced a fluctuation, ultimately rising by 0.59% during the trading session, with a transaction volume exceeding 21 million yuan [1] Group 2: Business Development Transactions - In May, at least six domestic innovative pharmaceutical companies announced business development (BD) transactions, primarily involving cross-border cooperation with foreign pharmaceutical companies [2] - The total value of BD transactions in innovative pharmaceuticals is projected to rise from $9.2 billion in 2020 to $52.3 billion by 2024, with upfront payments increasing from $600 million to $4.1 billion [2] - As of early 2025, the total value of innovative pharmaceuticals' overseas transactions has reached $45.5 billion, with upfront payments amounting to $2.2 billion, indicating a potential record year [2] Group 3: Industry Outlook - The pharmaceutical industry is expected to experience a structural turning point by 2025, driven by continuous policy optimization and the prominence of innovative and biological drugs [2][3] - The market size of the pharmaceutical industry is anticipated to exceed 8 trillion yuan, supported by an aging population and upgraded health consumption [3] - The valuation of the industry is currently at historical lows, suggesting potential for valuation recovery and performance growth in the future [3]

Group 1 - Company X plans to purchase servers from multiple suppliers for a total amount not exceeding 4 billion yuan, primarily for providing computing power leasing services [1] - The transaction amount accounts for over 50% of the company's latest audited net assets and total assets, requiring approval from the shareholders' meeting [1] Group 2 - Company Y's stock has hit the limit up for four consecutive trading days, with a cumulative increase of 46.44%, indicating significant market interest in its cultural and creative business [2] - The volatility of the cultural and creative business is substantial, with projected revenues of 88.68 million yuan, 54.17 million yuan, and 184.62 million yuan for the years 2022 to 2024 respectively [2] - The main business remains focused on cigarette labels despite the fluctuations in the cultural and creative sector [2] Group 3 - Company Z's controlling shareholder is planning a change in control, intending to transfer 72.4276 million shares, representing 22.396% of the total share capital, to another investment group [3] - The stock will be suspended from trading starting May 28, 2025, for a period not exceeding two trading days [3] Group 4 - Company A has submitted an application for the issuance and listing of H-shares on the Hong Kong Stock Exchange [4] - The application materials are subject to updates and revisions as per the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [4] Group 5 - Company B's wholly-owned subsidiary plans to acquire 100% of the Czech IMI company for approximately 9.425567 million euros, aiming to enhance its global strategy and production layout [5] - The acquisition does not constitute a related party transaction or a major asset restructuring and does not require shareholder approval [5] Group 6 - Company C reported that its production costs and sales have not experienced significant fluctuations, despite its stock price deviating by over 20% in recent trading days [6] - The company confirmed that there are no undisclosed significant matters related to its operations or its controlling shareholders [6] Group 7 - Company D's stock has been trading with high volatility, with a TTM price-to-earnings ratio of 73.68, significantly above the industry median of 31.76 [7] - The company has a trading turnover rate of 19.65% as of May 27 [7] Group 8 - Company E has confirmed that its recent operational conditions and external business environment have not undergone significant changes, despite stock price fluctuations [9] - The company has no undisclosed significant matters or ongoing major plans [9] Group 9 - Company F's actual controller sold 0.26% of the company's shares during a period of stock price volatility, with proceeds partially allocated for land purchases and factory construction [10] - The actual controller may consider further stock purchases based on market conditions [10] Group 10 - Company G announced that a recent certification for its subsidiary's products will not have a direct impact on its revenue or profits [11] - The stock has also experienced significant price fluctuations recently [11] Group 11 - Company H has decided to terminate the restructuring plan for its subsidiaries due to a lack of consensus on transaction terms and changes in market conditions [12] - The decision is expected to have no adverse effects on shareholder interests [12]

Investment Rating - The report does not explicitly state an investment rating for the GLP-1RA industry Core Insights - The GLP-1RA market in China is expected to experience significant growth due to increasing diabetes and obesity rates, with a projected market size of 717 billion yuan by 2029, reflecting a compound annual growth rate (CAGR) of 22.2% from 2024 to 2029 [26][27] - The demand for GLP-1RA drugs is driven by their dual efficacy in blood sugar control and weight management, particularly among the population with obesity and diabetes [4][22] - The industry is characterized by a competitive landscape dominated by multinational corporations, with domestic companies rapidly catching up through innovation and generic drug development [5][68] Summary by Sections Industry Overview - The GLP-1RA class of drugs has shown significant advancements in weight management and is being explored for applications in cardiovascular and renal diseases [2][4] - The Chinese government has initiated policies to promote weight management, which is expected to enhance the market for GLP-1RA drugs [2] Market Size - The GLP-1RA market in China grew from 9.62 billion yuan in 2020 to 10.74 billion yuan in 2023, with a CAGR of 3.7% [26] - The market is projected to reach 71.7 billion yuan by 2029, driven by favorable insurance policies and expanding indications for use [26][27] Industry Chain Analysis - The GLP-1RA industry chain consists of upstream raw material suppliers, midstream manufacturers, and downstream sales channels, with a focus on the production of peptide raw materials [31][34] - The upstream market is characterized by a limited number of suppliers, with Chinese companies expected to gain a competitive edge due to cost advantages as patents expire [38][40] Competitive Landscape - The GLP-1RA market features a three-tier competition structure, with multinational companies leading innovation, domestic firms rapidly following, and biotech companies carving out niche markets [68] - Future competition will focus on innovations in long-acting formulations, oral delivery methods, and multi-target therapies [71] Company Analysis - East China Pharmaceutical has developed a comprehensive product matrix covering the entire lifecycle of GLP-1RA drugs, balancing commercial products with innovative pipelines [80] - The company has successfully launched the first GLP-1RA for weight management in China and is advancing multiple-target GLP-1RA candidates [80]

剂型：片剂 规格：50mg 申请事项：药品注册（境内生产） 证券代码：688076 证券简称：诺泰生物 公告编号：2025-047 江苏诺泰澳赛诺生物制药股份有限公司 关于自愿披露马来酸氟伏沙明片获得药品注册证书 的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）于近日收到国 家药品监督管理局核准签发的马来酸氟伏沙明片的《药品注册证书》（证书编号： 2025S01365），现将相关情况公告如下： 一、《药品注册证书》的主要内容 药品名称：马来酸氟伏沙明片 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 二、药品相关情况 马来酸氟伏沙明片是一种 SSRIs 类抗抑郁药，用于治疗抑郁症和强迫症。马 来酸氟伏沙明片由雅培制药（Abbott Laboratories (Singapore) Pri ...

证券代码：688076 证券简称：诺泰生物 公告编号：2025-046 资本公积转增股本总额:公司 2024 年度拟以资本公积向全体股东每 10 股转增 4 股不变，转增股本的数量由 87,912,038 股调整为 89,948,366 股（具体 以中国证券登记结算有限责任公司上海分公司最终登记结果为准，如有尾差，系 取整所致）。 本次调整原因:自 2025 年 3 月 31 日至本公告披露日，公司公开发行的可 转换公司债券"诺泰转债"处于转股期，转股数量为 5,090,821 股。上述事项导 致公司总股本由 219,780,094 股增加至 224,870,915 股。公司按照维持每股分配 比例不变、每股转增比例不变的原则，对公司 2024 年度利润分配及资本公积转 增股本方案中的现金分红总额、转增股本总额进行相应调整（具体以中国证券登 记结算有限责任公司上海分公司最终登记结果为准，如有尾差，系取整所致）。 一、调整前利润分配、资本公积转增股本方案 江苏诺泰澳赛诺生物制药股份有限公司 关于调整 2024 年度利润分配现金分红总额 及资本公积转增股本总额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚 ...